Introduction
Gene transfer into skeletal muscle is promising for the treatment of a variety of genetic disorders as well as for vaccination. Skeletal muscle has major advantages as a target tissue for gene delivery since it comprises a large percentage of body weight, it is easily accessible and it can secrete large amounts of recombinant proteins into the circulatory system. These properties make the skeletal muscle not only attractive for the potential treatment of muscle-based genetic disorders like dystrophies but also for the correction of serum protein deficiencies such as hemophilias or erythropoetin-responsive anemias.
To date, two fundamental strategies have been employed for delivery of genetic material to skeletal muscle. In ex vivo experiments, myoblasts were transduced with genetic material and reimplanted into mice. After stable incorporation into skeletal muscle these cells were shown to secret therapeutic levels of serum proteins for several months. 1, 2 In the more recent in vivo strategies, the vector carrying the therapeutic sequences was directly injected into skeletal muscle; the vectors used included plasmid DNA, [3] [4] [5] first-generation adenoviruses, 6, 7 helper-dependent adenoviral vectors, [8] [9] [10] and adeno-associated viruses. [11] [12] [13] [14] Although gene transfer can be obtained by direct intramuscular injection of first- accompanied by a cellular immune response in the infected muscle but was not connected with detectable expression of early or late genes of the viral backbone as analyzed by RT-PCR. A very low dose of OAVhaat (3 × 10 7 infectious particles) was sufficient to produce reasonable amounts (Ͼ100 ng/ml) of serum hAAT, and this was accompanied by a weak immune response to the vector. Under these conditions, a second intramuscular injection of the same recombinant OAV vector was successful. Our study expands the known tissue tropism of OAV-derived vectors in vivo and points to the possible utility of the vector for muscle gene transfer and vaccination. Gene Therapy (2000) 7, 1491-1498.
generation and helper-dependent human adenoviral vectors, infection of skeletal muscle using hAd vectors has turned out to be inefficient. Infectability of skeletal muscle was shown to be maturation-dependent, and inefficient uptake of adenovirus by mature skeletal muscle was most likely caused by down-regulation of both primary and secondary receptors for human C group adenoviruses during muscle development. [15] [16] [17] In addition, use of hAd vectors in humans will be complicated by the presence of pre-existing immunity to adenovirus vectors. More than 95% of the human population has antibodies directed against human adenoviruses, and a long-lived CD4 + T cell response was observed in a large percentage of healthy cohorts. [18] [19] [20] Consequently, the inability of hAd vectors to transfer genes to immuno-competent animals successfully during a repeated administration principally reflects the situation in most humans before the first injection of hAd vectors. To overcome the pre-existing immunity to the vector and to achieve therapeutic effects, severe immuno suppression and high vector doses have been employed which might result in intolerable sideeffects in a therapeutic context.
To overcome the problem of pre-existing immunity to adenovirus vectors, we have used a vector based on ovine adenovirus isolate 287 (OAV) for gene transfer into mice. We demonstrated that this novel vector mediates gene transfer efficiently after systemic delivery or portal vein injection. 21, 22 OAV, which has been characterized in detail during the past few years, [23] [24] [25] [26] [27] [28] is the prototype of the recently proposed genus ATadenoviruses 29, 30 and is phylogenetically distinct from the mastadenoviruses (which include all known human adenoviruses). OAV has no typical E1A/B region, no obvious E3 region and a different genomic location of its putative E4 region. Moreover, sequences homologous to the genes coding for some structural proteins of human adenoviruses as well as a virus-associated RNA gene are absent from the OAV genome. Importantly, no pre-existing immunity to OAV in individual human sera or in human serum pools has been detected. 21 In this report we further investigated the in vivo characteristics of this novel vector system. We found that an OAV-derived vector can efficiently infect skeletal muscle in mice, which results in high level but transient reporter gene expression. Vector DNA was rapidly cleared from skeletal muscle but, in contrast to infection with a hAdderived vector, no residual expression of viral genes was detectable by RT-PCR. Our study sheds new light on OAV as a gene transfer vector and contributes to a better understanding of the in vivo behaviour of OAV-derived vectors.
Results
Efficient expression of haat cDNA after injection of OAVhaat into skeletal muscle To test whether OAVhaat was able to mediate reporter gene expression after injection into skeletal muscle, BALB/c and C57BL/6 mice were given a single injection of 1 × 10 9 infectious particles of OAVhaat into the quadriceps muscles (5 × 10 8 infectious particles into each hind leg). Three days later, blood was collected and hAAT levels were assayed in the sera by ELISA. As shown in Figure 1 , all mice expressed the transgene at moderate to high levels although expression levels in the BALB/c strain were lower. At day 14 post-injection (p.i.), serum hAAT levels were lower than 100 ng/ml in all animals, and by day 28 p.i. no hAAT was detectable. Interestingly, injection of a 10-fold higher dose (5 × 10 9 p.f.u. per hind leg) of a hAd vector containing the same expression cassette inserted into the E1 region resulted in significantly lower haat gene expression (Ͻ1 g/ml) at day 3 p.i. in both mouse strains (data not shown).
We next examined the site of transgene expression. BALB/c mice were injected as described above and killed at day 3 p.i. A non-infected animal was used as a control. Skeletal muscle as well as liver and spleen were examined for the presence of vector DNA by Southern blotting (Figure 2a) . Whereas strong signals for OAV-specific DNA were present in the skeletal muscle, no vector DNA was detectable by this method in liver and spleen indicating that the majority of the vector had not spread to the circulatory system. Investigation of RNA from the same samples of skeletal muscle showed a strong signal for haat-specific RNA in an RNase protection assay, indicating that the skeletal muscle was the site of haat mRNA synthesis (Figure 2b) .
Thus, OAV-based vectors efficiently infected skeletal muscle and led to a strong but transient transgene expression.
OAV-mediated gene expression is transient due to loss of vector DNA We next wished to know if the inability to detect serum hAAT at day 28 p.i. was due to the presence of antibodies to the transgene product (which might prevent its detection in serum) or loss of vector DNA from skeletal mus- cle. Several studies have shown that mouse strains differ in their ability to produce antibodies to secreted transgene products after systemic transduction with human adenoviral vectors. 31, 32 In BALB/c mice injected intramuscularly with OAVhaat at a dose of 1 × 10 9 infectious particles, anti-hAAT antibody titer at day 28 p.i. was higher than 1:100 000 in all animals investigated. To our surprise, C57BL/6 mice injected with OAVhaat also showed clear anti-hAAT antibody titers at day 28 p.i. which ranged between 1:1000 and 1:10 000. This differs from the situation observed with this mouse strain after infection with hAd vectors expressing haat or coagulation factor IX genes where no antibodies to these secreted transgenes were detected. [32] [33] [34] Southern blotting of DNA isolated from skeletal muscle of BALB/c mice killed at day 32 after injection of OAVhaat showed no signal specific for vector DNA (Figure 3a) . Thus, although antibodies to hAAT may have prevented its detection in mouse serum the loss of haat gene expression was clearly due to the loss of vector DNA from transduced skeletal muscle.
To investigate in more detail whether the loss of vector DNA was caused by the vector backbone or by the transgene expressed in the infected cells, we constructed a vector which contained only a small polylinker (OAVpoly) in place of the transgene. This vector was administered to BALB/c mice by an i.m. injection and presence of vector DNA was analyzed by Southern blotting of muscle DNA at several time-points after injection. A severe drop in the amount of OAV-specific DNA was observed between day 3 and 14 p.i., but OAV DNA remained detectable until day 31 ( Figure 3b ). The same phenomenon was observed after intraportal injection of 
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OAVpoly, where a small amount of OAV-specific DNA remained detectable in liver until at least day 28 (P Lö ser, unpublished results).
Immune response to OAV vector and lack of expression of OAV genes after infection of mouse skeletal muscle Injection of mouse skeletal muscle with first-generation hAd vectors results in leukocyte infiltration of the infected tissue and activation of a T cell subset. 35, 36 This is believed to be caused, at least in part, by a residual expression of genes from the viral backbone of the vector, and presence of viral gene products has been shown in vivo after infection of liver and lung with first-generation hAd vectors. [37] [38] [39] We wished to know if infection of mouse skeletal muscle with a OAV vector would result in T cell activation which might be responsible for vector clearance. For this reason, BALB/c mice were injected with 5 × 10 8 infectious particles of OAVhaat into the right quadriceps muscle, mice were killed at day 8 p.i. and sections of the infected muscle were stained for the presence of CD4
+ and CD8 + T cells. As shown in Figure 4 , infiltration of OAV-infected muscle with both types of T cells was clearly detectable indicating that loss of vector might be due to a cellular immune response to the OAV vector.
We further wished to know whether infecting the skeletal muscle of mice with OAV would result in the expression of early or late OAV genes. Therefore, quadriceps muscles of BALB/c mice were infected with a high dose (10 9 infectious particles) of OAVhaat or, as a control, 10 10 infectious particles of Ad5haat. The 10-fold higher dose of Ad5haat was chosen because this dose was necessary to obtain clearly detectable serum hAAT levels after intramuscular injection. Muscle tissue was harvested at 20 and 40 h p.i. and total RNA from skeletal muscle was analyzed for selected OAV-or Ad5-specific transcripts by RT-PCR. RNAs from OAV-infected CSL-503 cells or Ad5-infected 293 cells, respectively, were used as positive controls while uninfected mouse skeletal muscle served as a negative control. To exclude false positive results due to OAV or Ad5 DNA contamination of the RNA preparations, RNA from uninfected skeletal muscle was spiked with 1 g of OAV or Ad5 DNA before DNase digestion during the process of RNA preparation. In addition, spliced RNA species were chosen for amplification. 27 The results for two major OAV early genes, ORF3 from the putative E4 region and DNA binding protein, are shown in Figure 5a and b, respectively. Products of about 1000 and 470 bp, respectively, were amplified from spliced mRNAs present in permissive CSL-503 cells although clear differences in the amount of these transcripts were seen at 20 and 40 h p.i. (Figure 5a and b, lanes 8 and 9). No PCR product was detectable with RNA isolated from OAV-infected mouse muscle (Figure 4a Thus, genes present in the Ad5 vector backbone were expressed to some extent in mouse skeletal muscle but no expression from the OAV genome was detected for any of the viral genes investigated. Therefore, residual expression of OAV genes was not the major reason for clearance of the vector from mouse skeletal muscle.
Readministration of OAV-derived vectors
As OAV infects skeletal muscle very efficiently we reasoned that low doses of this vector might be sufficient to produce detectable amounts of the transgene product while inducing a low-level antibody response. Successful readministration of the same vector might therefore be possible. C57BL/6 mice were injected in the right hind leg with decreasing doses of OAVhaat and serum hAAT was assayed at day 3 p.i. As expected, decreasing vector doses resulted in lower serum hAAT levels, but even with as little as 3 × 10 7 infectious particles Ͼ100 ng per milliliter of the transgene product was still detectable (Figure 7 ). All animals raised antibodies to both the transgene product (1:10 000 to 1:100) and to the vector (1:1280 to 1:80) in proportion with the virus dose.
A second i.m. injection of 5 × 10 8 infectious particles of OAVhaat was given in the left hind leg 35 days after the initial injection and serum hAAT was assayed 3 days later. Whereas mice that had received a higher initial dose of OAVhaat at the first injection (10 9 to 2.5 × 10 8 infectious particles) did not produce detectable serum hAAT, mice that had initially received a lower dose (1.2 × 10 8 to 3 × 10 7 infectious particles) produced hAAT at a moderate level (250-2300 ng/ml serum). Thus, a repeated infection with low doses of an OAV-derived vector was possible.
Discussion
Gene delivery into muscle tissue may provide a route of administration for genes whose products can be secreted into the bloodstream, or for vaccination. Two major hurdles for the use of hAd vectors in gene transfer to skeletal muscle are apparent. First, infection of skeletal muscle was ineffective in most cases, probably due to down-regulation of the receptors for C group adenoviruses in skeletal muscle during myogenesis. This was 
RNA (2 g) was reverse transcribed and amplified using primer pairs specific for E4ORF6 (a) and DNA binding protein (b)
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infectious particles of OAVhaat into the left quadriceps muscle and haat gene expression was measured 3 days later. Dark bars, first injection; light grey bars, second injection.
Gene Therapy shown for ␣ 5 integrins and CAR in mice 15, 17 as well as in human myoblast cell culture. 16 Alteration of the tropism of hAd vectors did not improve the transducibility of mouse skeletal muscle. In addition, the extracellular matrix that surrounds muscle fibers blocks viral penetration of the myofibers. 40 Second, and even more importantly, pre-existing immunity to hAd vectors severely impairs the ability of hAd vectors to infect skeletal muscle. For example, intramuscular injection of an hAd vector encoding the coagulation factor IX gene into Swiss-Webster mice pre-immunized intramuscularly with a lacZ encoding hAd vector resulted in less than 20% of the transgene expression obtained in non-immunized mice. 6 Immunization of BALB/c mice by systemic application of a hAd vector encoding no transgene completely abolished the ability of Ad5haat injected intramuscularly 4 weeks later to mediate transgene expression in these mice, even though antibody titers to the initial hAd vector were only 1:20 to 1:80 at the time of second vector application (P Lö ser, unpublished results). Thus, preimmunity to hAd vectors, which is common in humans [18] [19] [20] is likely to preclude the use of hAd vectors for many applications.
We and others 21, 41 have, therefore, suggested the use of adenoviral vectors of non-human origin for gene therapy approaches. Vectors derived from ovine adenovirus isolate 287 (OAV) were shown to transduce efficiently cells in vivo after delivery to mice either systemically or locally via the portal vein. 22 Unlike hAd vectors which predominantly infect the liver in rodents, OAV was distributed more evenly among the organs in mice. 21, 22 In the present study we investigated the potential of OAV to infect skeletal muscle because we wished to know if this new vector system could infect this tissue efficiently and therefore have the capacity to serve as a gene therapy and/or vaccination agent. We found that a single injection of OAVhaat into the quadriceps muscle of both BALB/c and C57BL/6 mice produced moderate to strong but transient haat gene expression. Vector DNA was shown to be present predominantly in the skeletal muscle and this was also the site of transgene expression.
In contrast to hAd vectors, OAV infected mouse skeletal muscle very efficiently, with as little as 3 × 10 7 infectious particles producing Ͼ100 ng/ml serum hAAT at day 3 p.i. Moreover, the dose-response relationship of vector used and transgene expression observed was essentially linear. This is different to the situation with hAd vectors where a threshold effect was observed. 42 However, this study was performed using systemic delivery of the hAd vector, and the results might be different when the vector is injected directly into skeletal muscle.
The temporal pattern of OAV-mediated haat gene expression in immuno-competent mice was similar to that observed by others with first-generation hAd vectors after intramuscular injection. 6 The maximum level was observed at day 3 p.i. but this rapidly declined until day 14. Although both mouse strains used in our study developed antibodies to the transgene product, and these can prevent detection of hAAT by ELISA, the decline in transgene expression was clearly due to the loss of vector DNA from skeletal muscle. Unlike studies with hAd vectors coding for foreign transgenes where lowering the vector dose produced prolonged transgene expression, 33 ,43 a rapid loss of OAV-mediated haat gene expression was observed even with the lowest dose used (data not shown). However, the efficiency of OAVmediated gene transfer to skeletal muscle allowed successful readministration of the same vector. The initial low vector dose (Ͻ1.2 × 10 8 infectious particles) gave rise to clear transgene expression but caused only a weak immune response to the vector in C57BL/6 mice. Therefore, it was possible to reinject the vector at a higher dose (5 × 10 8 infectious particles) and to obtain moderate gene expression after this second administration. Rothel and colleagues 44 have previously reported the use of an OAVderived vector expressing the 45W antigen from the cestode parasite Taenia ovis for vaccination of sheep. In their study, a second injection of the vector did not result in a boost of anti-45W IgG titre suggesting that a robust immune response to the vector prevented it from infecting the target cells. However, sheep is the natural OAV host and it is possible that expression of OAV genes in ovine muscle leads to a much more pronounced immune response to the vector than in non-permissive animals like mice.
As observed previously in studies with human adenovirus vectors, a T cell response was also induced by OAV in mouse skeletal muscle which involved both CD4 + and CD8 + cells. The character of the immune response in skeletal muscle to hAd vectors has been investigated previously. 35, 36 However, in both studies the highly immunogenic lacZ gene was used as a transgene, and data on contribution of transgene products and vector proteins to the development of a cellular immune response remained contradictory. In case of OAVmediated induction of T cell response and subsequent vector clearance from infected mouse muscle, the involvement of two possible sources of antigen was investigated. First, we followed the time-course of the presence of vector DNA in skeletal muscle when an OAV vector encoding no transgene was injected. As with OAVhaat, most of the vector DNA was lost from skeletal muscle of Balb/C mice within 2 weeks, and only a small amount of vector DNA remained detectable at day 31 p.i. In contrast, a hAd vector which contained a promoter and polyA signal but no coding sequence remained stable in the muscle of C57BL/6 mice for 4 weeks and was cleared less rapidly from the skeletal muscle of BALB/c mice than the empty OAV vector (data not shown). Others have shown using a hAd vector in CD1 mice that intramuscular injection provided long-term gene expression if the transgene encoded a self-protein. 45 Thus, although some OAV vector DNA remained detectable for at least 31 days, an immune response to the vector seems to occur which, however, might be insufficient to clear the vector completely from the infected skeletal muscle. Second, we investigated the involvement of possible OAV gene expression in the process of vector loss. Yang and co-workers 36 observed an in vitro CTL response to viral proteins after intramuscular injection of a hAd vector into mice transgenic for the lacZ gene, although the in vivo relevance of these data remained questionable. This CTL response was not induced when the vector was UV-inactivated before infection. In addition, low expression of early and late hAd genes was suggested to play a role in vector clearance from liver 37 and lung. 38, 39 Extensive immune infiltrates after intramuscular injection of several hAd vectors were also observed by Kafri and co-workers 46 in both BALB/c and C57BL/6 mice, but in this study immune infiltrates were present even after administration of a vector which had been inactivated by UV in the presence of psoralen before administration. These authors suggested a mechanism for vector clearance which is independent of viral protein synthesis in the infected cells and based on MHC-I processing and presentation of the viral capsid. This mechanism might hold true for the OAV infection of skeletal muscle, since our RT-PCR results did not reveal the expression of any OAV gene investigated. This is in contrast to the situation after infection of skeletal muscle with a hAd vector where transcripts of major early hAd genes were detected and was not due to the timing of OAV infection in muscle since haat gene expression was already observed at Ͻ30 h after vector injection (data not shown).Thus, mechanisms by which the vector is cleared from the skeletal muscle in mice might be different for OAV and hAdderived vectors. Moreover, in skeletal muscle the T cell response to products of genes transduced by hAd vectors was shown to be dependent on the ability of these vectors to infect dendritic cells. 47 Preliminary results from ex vivo infection of dendritic cells suggest that OAV indeed infects this cell type efficiently. Therefore, differences between OAV and hAd-derived vectors in their ability to infect antigen-presenting cells could also explain the different clearance rates of these vector types from infected skeletal muscle.
In summary, we have shown that OAV vectors are vehicles for efficient gene transfer into murine skeletal muscle. This novel vector type combines the advantage of high transgene expression with the resistance to immunity to hAd vectors and points to the possible utility of currently available OAV vectors for short-term gene delivery including vaccination.
Materials and methods
Cells and viruses HEK-293 cells (human embryonic kidney, permissive for E1-deleted human adenoviruses) were cultured in Dulbecco's modified Eagle's medium (GibcoBRL, Karlsruhe, Germany) with 2 mm glutamine (Sigma, Deisenhofen, Germany) and 10% fetal calf serum (Roche Diagnostics, Mannheim, Germany) at 5% CO 2 . CSL-503 cells (fetal ovine lung, permissive for OAV 48 ) were grown under the same conditions but in 15% fetal calf serum. The generation of OAVhaat in which expression of the human ␣ 1 -antitrypsin (haat) cDNA is driven by the RSV 3′LTR has been described. 21 OAVpoly contains a short polylinker at the same site of the OAV genome instead of the haat expression cassette and was constructed using a cosmidbased cloning system (Hillgenberg et al, unpublished data). Ad5haat, an E1-deleted first-generation vector that contains the identical haat expression cassette to OAVhaat, was a generous gift of Mark Kay, Stanford University, USA. Viruses were grown on permissive cell lines and purified as described previously. 49 Virus titers were determined by an end-point dilution assay on permissive cell lines, and typical titers for OAV and Ad5 vectors were 0.5-1 × 10 10 and 0.5-1 × 10 11 infectious particles per milliliter, respectively. Particle/infectious particle ratios for Ad5 and OAV recombinants were Ͻ40:1.
Animal procedures and analysis of mouse sera Eight-week-old female BALB/c and C57BL/6 mice were obtained from Charles River, Sulzfield, Germany. Mice were given intramuscular injections into quadriceps muscles using a maximum volume of 75 l per injection. Blood was collected from the orbital sinus of anesthetized mice to measure serum ␣ 1 -antitrypsin. The enzymelinked immunosorbant assay used for quantification of hAAT in serum is described elsewhere. 50 The titer of neutralizing antibodies to viral vectors was determined by the ability of sera to inhibit infection of 293 cells by hAd vectors and of CSL-503 cells by OAV vectors as described previously. 21 The antibody titer to hAAT in serum was measured according to the method described elsewhere.
33
CD4 and CD8 immunohistochemistry BALB/c mice were injected into quadriceps muscle with 5 × 10 8 infectious particles of OAVhaat or PBS, respectively, and animals were analysed for successful infection by ELISA for serum hAAT at day 3 p.i. At day 8 p.i., animals were killed and quadriceps muscles were isolated and frozen in liquid nitrogen/isopentan. Frozen sections from quadriceps muscle (8 m) were fixed in methanol, thawed and incubated for 60 min in blocking buffer (RPMI + 10% fetal calf serum + 10% goat serum). Sections were then incubated for 60 min in PBS (supplemented with 10% fetal calf serum and 1% bovine serum albumin) with rat anti-mouse CD4 (L3T4), rat antimouse CD8a (Ly-2) or rat IgG 2a as isotype control, respectively, at 10 g/ml (all antibodies from Pharmingen, San Diego, CA, USA) followed by incubation with an alkaline phosphatase-conjugated goat anti-rat IgG (Jackson ImmunoResearch, West Grove, PA, USA) at 10 g/ml for 60 min. Alkaline phosphatase activity was visualized using the Fast Red Substrate System (DAKO, Carpinteria, CA, USA). Sections were stained with Mayer's hematoxylin solution (Sigma Diagnostics, St Louis, MO, USA) and examined microscopically.
Analysis of DNA and RNA DNA and total RNA from mouse tissues and cultured cells were isolated using standard methods. Southern blotting for detection of OAV-specific DNA in genomic DNA (20 g) extracted from mouse tissues was performed as described previously. 21 RNase protection assays were carried out with 20 g of total RNA from skeletal muscle following standard procedures. A radiolabelled RNA fragment of 362 bases comprising the EcoNI fragment of human hAAT cDNA was used as a probe.
RT-PCR was performed with 2 g of total RNA from skeletal muscle utilizing the Titan kit (Roche Diagnostics, Mannheim, Germany) and following the instructions of the manufacturer. The primers for amplification of the cDNA were AK33/AK37 for OAV E4 and AK28/AK32 for DNA binding protein. 27 For amplification of OAV pVII and hexon cDNAs the primers 5′-GGAACAT-CAAGTATGAGGGC-3′ (pVII-1), 5′-TTAAGTCGATCC GCAGGAG-3′ (pVII-2), 5′-CTACTGGTGCTTCTGGAA GG-3′ (hexon-1) and 5′-CCGTAAGAGTTGGTGTCATC-3′ (hexon-2) were used. Primers for amplification of Ad5 E4ORF6 and DNA binding protein transcripts were 5′-CATGGCAGTGGTCTCCTCAG-3′ (E4ORF6-1), 5′-CAC-TACGACCAACACGATCTC-3′ (E4ORF6-2), 5′-GAG CCGATATCTTGAAGTC-3′ (DBP-1) and 5′-AACGene Therapy TACTGCCTGACCAAGTG-3′ (DBP-2). GAPDH cDNA was amplified with primers which bind to cDNAs from both mouse and sheep. All PCRs were performed for 40 cycles. As controls, 0.5 g of total RNA from 293 or CSL-503 cells infected with Ad5haat or OAVhaat, respectively, at a MOI of 1, were used. To prevent false-positive signals from contaminating viral DNAs, 1 g of virus DNA was added to negative controls before DNase digestion during RNA preparation.
